Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
8.21
-0.16 (-1.91%)
May 26, 2026, 4:00 PM EDT - Market closed
Upstream Bio Revenue
Upstream Bio had revenue of $1.03M in the quarter ending March 31, 2026, with 82.69% growth. This brings the company's revenue in the last twelve months to $3.32M, up 44.69% year-over-year. In the year 2025, Upstream Bio had annual revenue of $2.85M with 20.42% growth.
Revenue (ttm)
$3.32M
Revenue Growth
+44.69%
P/S Ratio
134.49
Revenue / Employee
$44,293
Employees
75
Market Cap
446.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.85M | 484.00K | 20.42% |
| Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
| Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
| Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 8 days ago - Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug - TheFly
- 8 days ago - Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - GlobeNewsWire
- 12 days ago - Upstream Bio price target lowered to $50 from $51 at Mizuho - TheFly
- 13 days ago - Upstream Bio reports Q1 revenue $1.03M, consensus $347,170 - TheFly
- 13 days ago - Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 13 days ago - Upstream Bio Earnings release: Q1 2026 - Filings
- 13 days ago - Upstream Bio Quarterly report: Q1 2026 - Filings
- 13 days ago - Upstream Bio Slides: Corporate presentation - Filings